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INTRODUCTION: 
Acquired aplastic anemia (AA) is a rare disease of unknown pathogenesis and 
disputed etiology. The diagnosis is based on the criteria proposed by international 
aplastic anemia and agranulocytosis study group (1).  
 
There are several etiological factors proposed for the same based on epidemiological 
studies which include drugs, toxic chemicals, radiation,etc. Most cases of aplastic 
anemia have an immune mediated pathogenesis (2). This is revealed by its response to 
immunosuppressive drugs. However non immune factors also play an important role. 
The role of HLA DR2 allele, cytokine gene polymorphisms and telomeres in aplastic 
anemia have been widely discussed (3).  
 
The treatment of choice of acquired aplastic anemia in young patients without 
comorbidities is haematopoietic stem cell transplant. Other important treatment 
modality is immunosuppressive drugs. Androgenic steroids gives good response in a 
subset of patients with acquired aplastic anemia. The exact mechanism of action is 
however not known. Recent studies have shown that it tends to protect from telomere 
shortening in haematopoietic tissues by increasing Telomerase activity (4), the 
specialized reverse transcriptase which helps in adding telomeres to chromosome 
ends.  
 
This study seeks to analyse the role of androgenic steroids in acquired aplastic anemia 
–its efficacy and predictors of response. 
  
 
Review of Literature 
 
2 
 
REVIEW OF LITERATURE: 
ACQUIRED APLASTIC ANEMIA- DEFINITION AND DIAGNOSIS 
Acquired aplastic anemia (AA) is a rare disease of unknown pathogenesis and 
disputed etiology. In the past there was difficulty in finding out the exact incidence 
due to lack of strict diagnostic criteria. It is characterized by pancytopenia with other 
blood cells being morphologically normal. The diagnostic criteria of aplastic anemia 
and its classification based on its severity is depicted in the table (table: A) below (1). 
Table: A.           Definition of Aplastic anemia with severity criteria 
Classification Criteria 
Severe BM cellularity < 25% (or <50% if <30% of BM is haematopoietic 
cells) and ≥ 2 of the following: 
Peripheral blood neutrophil count <0.5 x 109/L 
Peripheral blood platelet count <20 x 109/L 
Peripheral blood reticulocyte count <20 x 109/L 
Very severe Peripheral blood neutrophil count <0.2 x 109/L 
 
Non severe 
Hypocellular BM , peripheral blood values not meeting the criteria 
for severe disease. 
  
There may be red cell anisocytosis, toxic granulation in neutrophils and decrease in 
mean platelet volume all reflecting decreased production of cells in bone marrow (5). 
In the bone marrow there is increase in fat without increase in reticulin and no 
increase in abnormal cells. There may be islands of haematopoietic tissue with normal 
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cellularity along with the hypocellularity. So a bone marrow report showing normal 
cellularity may sometimes confuse the diagnosis. Aplastic anemia can closely 
resemble hypoplastic Myelodysplastic syndrome (MDS). Few cases can transform to 
MDS or acute leukemia and can also develop a clone of PNH (paroxysmal nocturnal 
haemoglobinuria) cells. 
DIFFERENTIAL DIAGNOSIS: 
Constitutional marrow failure syndromes like Fanconi anemia and Myelodysplastic 
syndromes have to be ruled out before the diagnosis of acquired aplastic anemia. 
Fanconi anemia is diagnosed by morphological abnormalities which will be evident 
on physical examination and by chromosomal breakage studies. The diagnosis of 
other rare marrow failure syndromes is more difficult.  
MDS is diagnosed by bone marrow morphology and histology and cytogenetic 
studies. Marked hemophagocytosis, obvious dysplasia, or increased blasts suggests 
other diseases, although differentiation of hypocellular myelodysplastic syndrome 
from aplastic anemia can be difficult. Megakaryocytes are the most reliable lineage 
for distinguishing MDS from SAA.  Small mononuclear or aberrant megakaryocytes 
are typical of MDS, whereas megakaryocytes are markedly reduced or absent in SAA. 
In contrast, dysplastic erythropoiesis are not uncommon in an aplastic marrow, 
especially when a PNH is present (6).  It is difficult to differentiate aplastic anemia 
and MDS by bone marrow cytogenetic studies alone because hypocellular marrow of 
aplastic anemia may not yield sufficient metaphases for cytogenetic studies.  
Other important differential diagnosis to be ruled out from history and laboratory tests 
are aplasia associated with drugs, pregnancy, viruses, PNH, myelofibrosis and 
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haematological malignancies. Aplastic anemia and PNH overlap in approximately 
40% to 50% of cases (the AA/PNH syndrome) (7). 
EPIDEMIOLOGY OF APLASTIC ANEMIA: 
The first description of a case of Aplastic anemia was by Ehrlich in the later part of 
nineteenth century, where he described case of a young woman with severe 
pancytopenia who had a fatal outcome and whose autopsy revealed a yellow marrow. 
The name aplastic was introduced by Vaquez and Aubertin in 1904 (2).  Since then 
there were various case descriptions of aplastic anemia.  
There have been attempts to describe the epidemiology of disease including 
incidence, mortality and survival trends across the world. There was marked 
geographic variation in the prevalence of aplastic anemia, most being reported from 
Asian countries rather than from Europe or United States. 
Two large, population-based studies have been conducted, the International Aplastic 
Anemia and Agranulocytosis Study in Europe and Israel in the 1980s and Thai 
NHLBI Aplastic Anemia Study in Bangkok and a northeast rural region to find the 
etiology of aplastic anemia (8). The study was an international collaborative effort 
with participating centers in Israel, West Germany, Italy, Spain, Hungary, Bulgaria, 
and Sweden; the total population base was approximately 22 million people. The 
annual incidence of aplastic anemia ranged from 0.7-4.1 cases per million in these 
studies. Bangkok had the highest incidence of aplastic anemia when compared to 
other regions. 
The incidence reported by Montané et al. of 2.34/million(9) is similar to the rate of 
2.0 for the International Agranulocytosis and Aplastic Anemia Study in Europe and 
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Israel and Barcelona study is a partial continuation of this.  There were similar  
smaller national studies in France (10), the United Kingdom (11), Scandinavia, (12) 
and Brazil (13). 
However there are no published data on the exact incidence of acquired aplastic 
anemia among the Indian population. 
ETIOLOGY OF APLASTIC ANEMIA: 
There were many speculations about the cause of aplastic anemia. Aplastic anemia 
was previously linked to benzene especially among Swedish bicycle makers (14) , 
pharmaceutical drug use esp. Choramphenicol, malarial prophylactic drug use (15) 
etc. From population studies environmental factors appears to be more important than 
genetic factors in the etiology of Aplastic Anemia. 
Many etiologies have been proposed suggesting  an immune pathogenesis of aplastic 
anemia. Pregnancy was found to have a definite correlation and blood counts have 
been shown to improve after termination of pregnancy (16).  Similarly immune 
activation is thought to underlie aplastic anemia which develop secondary to nonviral 
hepatitis. There were previous associations of benzene with bone marrow failure. 
Benzene is known to interfere with immune function (17). 
Aplastic anemia occurring as an idiosyncratic reactions to drugs is rare. The genetic 
differences in drug metabolism can contribute to that. There were reports of 
carbamazepine and chloramphenicol causing bone marrow failure by the same 
process. Deletions in the glutathione S Transferase gene involved in carbamazepine 
metabolism have been implicated (18). No definite mechanism has been found for 
Chloramphenicol and other drugs like Pencillamine and Gold. 
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In the International Aplastic Anemia and Agranulocytosis Study, numerous 
associations between drugs and both dyscrasias were quantified, and the study has 
proven to be a landmark investigation of these rare diseases. Agranulocytosis has 
been shown to be primarily a drug-induced disease, with approximately two-thirds of 
the cases accounted for by associated drugs identified in the study. By contrast, only 
about 25% of cases of aplastic anemia were accounted for by associated drugs, and 
the majority remain unexplained. Because of the rarity of the diseases, absolute risks 
for individual drugs were low. 
PATHOPHYSIOLOGY: 
Immune factors:  Immune hypothesis was suggested decades ago when autologous 
recovery of marrow function occurs after transplants which fail to engraft pointing 
towards the conditioning regimen as the treatment for altered immunity. Also 
observations were that transplants without conditioning regimen failed. This is also 
obvious from the response of Aplastic anemia patients to immunosuppressive drugs. 
Exposure to specific environmental precipitants, diverse host genetic risk factors, and 
individual differences in the characteristics of the immune response likely account for 
the disease’s infrequency, variations in its clinical behavior, and patterns of 
responsiveness to treatment (2). 
Early studies identified that invitro marrow cultures were inhibited by addition of 
lymphocytes and haematopoiesis improved after removal of these lymphocytes. These 
effector cells were identified by immunophenotyping as cytotoxic CD8+ T 
lymphocytes expressing Th1 cytokines (19). These clones have been shown to 
disappear with successful therapy and reappear with disease relapse. In rare instances 
a small T cell clone persists after therapy and represents T cell tolerance. The 
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evidence for T cell mediated attack on bone marrow can be found invivo and invitro. 
The cytokines like interferon gamma and tumour necrosis factor alpha induce death of 
CD34+ cells invitro through FAS dependent pathway of apoptosis.  Murine models 
have also been developed, in which infusion of parental lymph node cells to F1 
donors induces pancytopenia, marrow aplasia and death. However it is not known 
how the T cells gets activated in aplastic anemia. Polymorphisms involving cytokine 
genes (20), mutations of PRF1 (encoding Perforin implicated in familial 
haemophagocytosis is overexpressed in aplastic marrows) and SAP (implicated in X 
linked lymphoproliferation, SAP protein levels are diminished in aplastic anemia) 
have been found in aplastic marrows suggesting a genetic basis for T cell activation. 
Non Immune Factors:  Non immune mechanisms have also been suggested from the 
failure of people to respond to immune suppressive therapies. Disease refractoriness 
in such cases has been attributed to depletion of stem cell pool, or immunologic 
mechanisms not responsive to current treatment. Certain genetic risk factors also 
appear to contribute to the pathophysiology of Aplastic anemia. Aplastic anemia is 
linked to HLA class II antigen, DR2 especially in patients who are responsive and 
dependent on immunosuppressive drugs. Nucleotide polymorphisms in certain 
cytokine genes like TNF-α, γ-interferon, which is a regulator of immune response, 
and inherited mutations in the telomerase gene complex has been postulated. The 
defects in telomere repair leads to progressive telomere shortening and subsequently 
to marrow failure and aplastic anemia. Telomere shortening was initially blamed to be 
due to the shrunken stem cell pool in the bone marrow. Mutations in DKC1 and 
TERC have been identified in X linked and autosomal dominant forms of 
Dyskeratosis congenital (21), a constitutional marrow failure syndrome. Similar 
mutations have been found in acquired aplastic anemia. Likewise mutations in SBDS, 
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gene mutated in Schwachmann Diamond syndrome which has short telomeres have 
been seen in acquired aplastic anemia. However Telomeres are short in one third to 
one half of aplastic anemia patients, but such mutations are found in less than 10% 
patients. This may be due to mutations in other as such unidentified genes involved in 
telomere repair mechanism or it may be secondary to stem cell replication. 
Telomeres and their role in Aplastic Anemia: Structure and function of Telomeres 
and Related Structures: Telomeres are DNA-protein complexes at the ends of 
chromosomes that protect the chromosomes from degradation and aberrant 
recombination of chromosome ends(22). In human beings they are made up of 
TTAGGG tandem repeats and CCCTAA in the complementary strand. They serve 
several roles like helping formation of circular ends (t loop), protective protein shield 
(shelterin) (23), and substitution for coding sequences of important genes at the 
vulnerable ends of the chromosome. DNA polymerases are unable to replicate the 
ends of chromosomes, also known as end replication problem. So there is a loss of 50-
100kb DNA from the chromosome ends during the process of each cell division.  But 
it can be replicated by polymerases called telomerase, (22) a specialized polymerase 
with an integral RNA component containing a template element directing the addition 
of telomeric repeats to chromosome ends.  
When telomeres become critically short, protective responses are engaged: short 
telomeres recruit double-stranded DNA break markers, such as phosphorylated 
histone H2AX and DNA-damage checkpoint factors, and activate p53 through ATM, 
up-regulating the cell-cycle inhibitor p21 and blocking cell cycle in G1,.ultimately 
producing cell proliferation arrest and apoptosis (24). In the absence of telomeres and 
the cellular protective responses, erosion of the chromosomal ends eventually would 
cause genomic instability and gene attrition. 
9 
 
Structure of Telomere:  
  
 
Telomerase Complex: To counter telomere erosion, which was due to an end 
replication problem, cells with a high proliferative capacity, such as hematopoietic 
stem cells, express a specialized enzyme, a reverse transcriptase known as telomerase, 
which helps in extending telomeres by the addition of TTAGGG nucleotide repeats to 
the 3’ terminus of a chromosome’s DNA.; the lagging strand is then duplicated by 
DNA polymerase. The catalytic portion of telomerase contains 2 molecules of each 
component: the enzyme, telomerase reverse transcriptase or TERT; an RNA template, 
encoded by TERC; and dyskerin, encoded by DKC1. TERT belongs to a family of 
reverse transcriptases specialized in elongating telomeres. In humans, the RNA 
template TERC spans 451 nucleotides, including an 11-nucleotide–long template, and 
contains several conserved regions essential for its stability. TERC binds to other 
proteins: dyskerin, GAR, NHP2, and NOP10. Telomeres are capped by at least 6 
proteins (TRF1, TRF2, TPP1, POT1, TIN2, and Rap1), collectively known as 
shelterin, that physically shield the DNA(23).  Shelterin allows discrimination of 
telomeres from double-stranded DNA breaks; lack of shelterin allows telomeres to be 
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identified as double-stranded DNA breaks and triggers DNA repair.  Telomerase is 
regulated by a wide variety of genes. TERT is repressed by retinoblastoma protein 
(Rb) and cyclin-dependent kinase inhibitor p21WAF1. Conversely, c-Myc activates 
TERT gene expression. The TERT promoter contains estrogen receptor elements and 
in reproductive tissues, estrogen and androgens have important roles in regulating 
telomerase expression and activity. TERT phosphorylation is another mechanism of 
telomerase activity regulation. It was recently have discovered that both estrogen and 
androgens activate telomerase in hematopoietic cells, mediated by estrogen-estrogen 
receptor complex binding to estrogen response elements in the TERT promoter.  
Telomerase is constitutionally expressed in germ line cells and variably expressed in 
normal haematopoietic stem cells, activated T cells and germinal centre B cells as 
well as majority of human cancers (25). The length of telomeric repeats has been 
shown to decrease with cell division both in vivo and in vitro, and there is a age-
related decreases in mean telomere length of blood and marrow cells. The reverse of 
this can also happen, overexpression of telomerase can lead to lengthening of 
telomeres and immortalization of human epithelial cells and fibroblasts (26). 
 
Studies from UK by Sarah E Ball and colleagues in 1998 tried to analyse whether the 
marrow failure in aplastic anemia and its transformation to secondary PNH and MDS 
are the result of the aging process as evidenced by decrease in telomere lengths (27). 
They found that there is accelerated shortening of telomeres beyond that is expected 
by age in primary aplastic anemia and secondary MDS patients , but not so much in 
secondary PNH patients. This was evident in both granulocyte and mononuclear cell 
populations suggesting that the process would have happened at the level of 
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haematopoietic stem cell level. There was also stabilization of the telomere shortening 
after normalisation of blood counts especially following transplants. They suggested 
further studies in telomere biology for further characteristion of the process.  Similar 
studies were conducted by Neil S Young and Blummendorf in 2001 to measure in 
Telomere length in leukocyte subpopulations ie. Peripheral blood lymphocytes and 
granulocytes in patients with aplastic anemia  by new method which combines 
fluorescent insitu hybridization with flow cytometry and found significant telomere 
length shortening in granulocytes more than that expected by age (28).  
 
Clonal Evolution: Aplastic anemia may coexist or may evolve into PNH or MDS. 
PNH clone detected in aplastic anemia are small and do not present with the typical 
hemolysis or thrombosis as classical PNH. Patients who evolve into MDS acquire 
chromosomal changes like aneuploidy- Trisomy 8, Monosomy 7. Monosomy 7 is the 
most frequent abnormality and it is associated with poor prognosis. Acute leukaemia 
has occurred as a terminal event in patients previously shown to have pancytopenia 
and marrow aplasia (Adams, 1951; Block, Jacobson, and Bethard, 1953). It is 
uncertain whether these represent two phases of the same illness or whether the 
fundamental disease is leukaemia with an unusual form of presentation.  Paroxysmal 
nocturnal haemoglobinuria (PNH) is another disease which may occur as a 
complication of aplastic anaemia, possibly with a greater frequency than hitherto 
recognized. 
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MANAGEMENT: 
Nonsevere aplastic anemia patients especially those who are not transfusion 
dependant, need observation alone. Those who progress to severe pancytopenia need 
treatment with transplantation or immunosuppressive therapy. 
Supportive Care: This includes management of infectious and haemorrhagic 
complications, expectant management of regimen related toxicities, provision of 
information and psychological support. Important facts like platelet transfusion 
threshold, (29) spectrum of infections (30) and antibiotic policies have been reviewed 
and revised frequently. Iron overload doesn’t seem to be a significant problem even in 
transfusion dependent patients. However iron chelation improves the serum ferritin 
and transaminase levels and in few instances associated with improvement in blood 
counts (31). 
Haematopoietic Stem Cell Transplantation: It is the treatment of choice (32) for 
young severe and very severe aplastic anemia who has a matched sibling donor. 
Conditioning regimen included Cyclophosphamide with or without additional agents. 
The survival of patients undergoing transplant have improved markedly over the 
recent years (32). Earlier the most important problem faced was graft rejection, which 
has now decreased with the use of more aggressive conditioning regimens, earlier 
treatment after diagnosis reducing the number of transfusions and use of less 
immunogenic blood products. The problem of chronic graft versus host disease 
(GVHD) still haunts the patient and the physician. In recent reporting by the Center 
for International Blood and Marrow Transplant Research of more than 1300 SAA 
patients who were transplanted from 1991 to 2004, survival at 5 years for patients 
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younger than 20 years of age was 82%, for those 20 to 40 years of age 72%, and for 
those older than 40 years, closer to 50%. 
 
Immunosuppressive Therapy (IST): Standard initial IST is horse Antithumocyte 
globulin (ATG) and Cyclosporine-A (CsA), which produces hematologic recovery in 
60% to 70% of cases and excellent long-term survival among responders, as shown in 
several large prospective studies in the United States, Europe, and Japan. A more 
lymphocytotoxic agent, rabbit ATG, has been successful in salvaging patients with 
refractory or relapsed severe AA (SAA) after initial horse ATG (33). However, in our 
recently reported large, randomized controlled study, hematologic response to rabbit 
ATG (37%) was about half that observed with standard horse ATG (68%), with 
inferior survival noted in the rabbit ATG arm. ATG is usually administered at a dose 
of 40 mg/kg over 4 hours, daily for 4 days. Prednisone 1 mg/kg is started on day 1 and 
continued for 2 weeks, as prophylaxis for serum sickness. Before each ATG dose with 
acetaminophen and diphenhydramine is given as premedication because infusion 
reactions are common.  
In patients who do not respond to immunosuppressive therapy and who do not have 
matched sibling donor for a transplant, other options are matched unrelated donor 
transplant/ (34) umbilical cord blood transplant (34).  Another option for patients who 
have limited resources and no matched sibling will be a trial of androgenic steroids. 
Androgens:  The introduction of androgens as haematopoietic stimulant for the 
treatment of aplastic anemia was in 1961 by Shahidi and Diamond (35). Early 
investigations had already proved the erythropoiesis stimulating activity of Androgens 
in mammals and Fowls. Also there were observations of increased haemoglobin in 
14 
 
conditions of androgen excess like Cushings syndrome and congenital adrenal 
hyperplasia and decreased haemoglobin in hypogondism. Similarly the haemoglobin 
levels were higher in adult males when compared to adult females which cannot be 
accounted by iron deficiency, pregnancy or blood loss. Another interesting 
observation was by B J Kennedy and associates who used Testosterone in women 
with breast cancer and found a high haemoglobin in these patients despite the disease 
being advanced and metatstatic to the marrow (36). Further androgens were used by 
Gardner and Pringle in patients with Myeloid Metaplasia (37). It was first used by 
Shahidi and Diamond in a patient with constitutional aplastic anemia and noted 
dramatic improvement in blood counts. Further investigations into the mechanism of 
action of Androgens led to different postulates like stimulation of erythropoietin 
secretion, stimulation of haematopoietic stem cells for increased DNA synthesis, and 
increased 2,3-Diphosphoglycerate synthesis which increases oxygen release in tissues. 
Later there were reports of Shahidi and Diamond regarding benefits of treatment with 
androgens in patients with acquired aplastic anemia (38).  Gardner and Pringle in 
1961 described a case of Chloramphenicol induced aplastic anemia who responded to 
androgens (37). 
In a study by Lewis published in 1965 in British Medical Journal from postgraduate 
medical school in London, there have been instances of remissions in patient 
receiving testosterone therapy, especially in children near puberty, but this treatment 
has usually been of less benefit in adult patients, and the  ultimate prognosis and 
median survival seemed little influenced by treatment with moderate doses of 
androgens and/or steroids (5). 
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Recently steroids have gone out of use due to lack of effectiveness and increased risk 
of infection. The androgens in common use recently is Danazol and Stanozolol. There 
are studies supporting efficacy of both. 
Another study from Chandigarh, India in 1991-2000, retrospectively analysed 49 
children with aplastic anemia including constitutional aplastic anemia who were 
treated with Stanozolol  and found that none of patients with very severe Aplastic 
anemia responded to therapy. 28.6% patients with severe aplastic anemia responded 
and 38% of patients with nonsevere aplastic anemia responded. Median time to 
respond was 11 weeks.  Poor prognostic factors were found to be short history of 
presentation (<3months) and more than or equal to 70% lymphoid cells in the marrow 
(39). 
In 2011, a study published in Annals of Haematology by Jaime-Perez J C and 
collegues, studied the effectiveness of Danazol as first line treatment of aplastic 
anemia. Overall response rate was 46% (17/37) in the danazol-treated group and the 
median time to initial response was 3 months (1-27). Tendency to achieve remission 
was similar among severity groups (P  =  0.094). The only adverse side effect 
recorded on the danazol group was an episode of gastrointestinal bleeding (40). 
There are also studies showing negative results proving androgens are ineffective. In 
the study by BM Camitta and collegues in 1979, failed to show any response to 
androgens. However this study has many limitations, important one being that this 
study was conducted on patients with only severe aplastic anemia whereas previous 
studies have shown that androgens work better in patients with nonsevere disease 
(41). 
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A study by Freiderick from Boston medical centre of 58 children with acquired 
aplastic anemia from 1958-70 also speaks against the effectiveness of androgens (42). 
They treated 57 patients with steroids and a variety of androgenic preparations 
(sublingual methyltestosterone or testosterone propionate (1-2 mg/kg daily), 
intramuscular testosterone enanthate (3 mg/kg twice weekly), oral fluoxymesterone 
(1-2 mg/kg daily), oral oxymetholone (3-6 mg/kg daily), and oral stanozolol (1-2 
mg/kg daily)) and supportive therapy. They observed a mortality of 71% over 10 year 
period. Similarly,in a study by Champlin et al in 1985, compared three treatment 
groups, patients who received ATG alone, ATG + androgens and ATG historical 
controls. There was no statistically significant difference in the response rates 
between three groups  if patients are stratified by age, sex, bone marrow cellularity, or 
etiology of aplastic anemia. Pretreatment peripheral blood counts were also not 
predictive of response. 
An adequate course of androgen is difficult to define, but most clinicians agree that as 
long as 3 mo of treatment may be required to induce an erythropoietic effect in 
patients with bone marrow failure of diverse etiologies. A rise in the neutrophil and 
platelet counts usually may be even more delayed. 
The commonly encountered side effects of androgen therapy are virilization, fluid 
retention, hyperlipidemia, acne, and more seriously, hepatic toxicity with cholestatic 
jaundice, peliosis hepatitis(42), and rarely, hepatoma (43). 
A search for the mechanism of action of androgens and how androgens work in 
constitutional anemias like Fanconis anemia, Dyskeratosis Congenita and some 
acquired aplastic anemias have throwed light into its role in increasing Telomerase 
activity in Haematopoietic tissues. Dyskeratosis congenita, is caused by mutations in 
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genes involved in telomere maintenance (DKC1 is mutated in X-linked dyskeratosis 
congenita; TERC, TERT, and TINF2 are mutated in autosomal dominant dyskeratosis 
congenita; and TERT, NOP10, and NHP2 are mutated in autosomal recessive 
dyskeratosis congenital (44). Mutations in TERT and TERC have been observed in 
acquired aplastic anemia (45). They appear to confer a genetic predisposition for the 
development of aplastic anemia. In vitro studies have been conducted on peripheral 
blood lymphocytes and bone marrow CD34+ cells in normal and TERT mutated 
patients. Androgens have been shown to increase telomerase activity as reflected by 
the increase in TERT mRNA levels in both these group of patients (4). The TERT 
promoter region contains an imperfect palindromic ERE at position -2677 and an ERE 
adjacent to an Sp1 site (Sp1-ERE) at position -873. Androgens may act on telomerase 
expression in hematopoietic tissue after conversion in peripheral tissues to 
metabolites, such as 17b-estradiol and 5a-dihydrotestosterone; leukocytes express 
aromatase (CYP19), the enzyme responsible for aromatization of the testosterone 
(46).  Estrogen receptor α , not estrogen receptor β is known to bind to these EREs 
and promote Telomerase gene expression (47).  For the same reason Tamoxifen, the 
drug used in Breast cancer is known to inhibit both estrogen and androgen effects on 
Telomerase. But Letrozole, an aromatase inhibitor blocks only androgenic action. 
Like  androgenic compounds , even estrogens may be even more effective in the 
future for the treatment of bone marrow failure syndromes. This is suggested by 
reports of bone marrow failure states remitting after the onset of puberty and the onset 
or relapse of bone marrow failure states during pregnancy when estrogen levels drop. 
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SUMMARY: 
The treatment of acquired aplastic anemia includes mainly allogeneic stem cell 
transplantation and immunosuppressive therapy (48).  Androgenic steroids can be 
tried in transplant ineligible and resource constraint situations. There are several 
studies supporting the same. The response to androgenic steroids was more in the 
nonsevere group of patients. Though the mechanism of action of androgens is still 
vague, there are several postulations regarding the same.  TERT and TERC gene 
mutations which is commonly seen in patients with Dyskeratosis congenital (21), a 
constitutional bone marrow failure syndrome, have been found in some patients with 
acquired  aplastic anemia. Androgens have been shown to act on estrogen receptor 
alpha (androgens gets converted to estrogens via aromatization in the periphery)  and 
activate the TERT gene , thereby increasing the telomerase levels which is known to 
decrease aging  of the haematopoietic tissues and hence apoptosis (4). Further studies 
are going on in this direction. 
 
 
 
 
 
 
 
 
  
 
Aims and Objectives 
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Aims and objectives:  
 
1. To analyze the clinical profile of patients (adults and children) with acquired 
aplastic anemia treated with androgenic steroids. 
2. To assess the response to androgenic steroids in the above patients with 
acquired aplastic anemia. 
3. To identify the demographic, clinical, and laboratory parameters that can 
predict response to androgenic steroids in the above mentioned patients. 
 
 
 
 
 
 
 
 
 
 
  
 
Patients and methods 
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Patients and Methods: 
This study protocol was approved by our Institutional Review Board (IRB). This is a 
retrospective analysis of patients diagnosed to have acquired aplastic anemia and 
treated with androgenic steroids from January 2008  to December 2012. 
Duration of the study:  June 2013 to March 2014.  
Settings of the study: Department of Clinical Haematology.  
Diagnostic criteria: Aplastic Anemia was diagnosed in patients presenting with 
cytopenia(s) (defined by International Agranulocytosis and Aplastic anemia study 
group in 1987 as presence of at least two of the following ie. Haemoglobin < 100g/L, 
neutrophil count < 1.5 x109/L and platelet count < 50 x 109/L) associated with a 
hypoplastic bone marrow (ie.bone marrow cellularity <25%, <50% if less <30% of 
the bone marrow is haematopoietic cells) (49).  
 
Patients: 
Inclusion Criteria: 
1.  All adults (age≥15 years) and children (age 1-14 years) diagnosed to have 
acquired Aplastic anemia and treated with androgenic steroids from 
January 2008 to December 2012, and with a follow up of at least 12 
weeks. 
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Exclusion Criteria:  
1. Patients with inherited bone marrow failure syndromes 
2. Patients who had been on any other medications prior to starting 
androgenic steroids. 
3. Patients on androgenic steroids with less than 12 weeks follow up.  
4. Patients with acquired Aplastic anemia and on androgenic steroids whose 
data are not retrievable. 
Methods: 
Collection of data: After approval by the IRB, the patient data base at our institution 
was reviewed to identify all patients (adults and children) diagnosed to have acquired 
Aplastic anemia at our institute from January 2008 to December 2012. Medical 
information regarding the clinical/laboratory details at diagnosis, post treatment 
response and adverse events were obtained from the hospital records (laboratory 
reports/ physician documentation in hospital charts/hospital discharge summaries). 
Only patients who had at least 12 weeks follow up after initiating therapy were 
categorized as ‘evaluable‘ for assessment of response and survival.  
Treatment: All patients who received androgenic steroids (ie; Danazol nad 
Stanozolol) as upfront therapy were included in the study. The dosages of the drugs 
prescribed to the patients were as follows; ie Danazol (400mg to 600mg per day in 2 
to 3 divided doses in adults, and 5mg/Kg/day in children), Stanozolol (20 – 60mg per 
day in 2 to 3 divided doses in adults and 1mg/Kg/day in children).  Data was collected 
with regard to type of treatment, duration of treatment, side effects and overall 
outcome with respect to the treatment given. 
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Data analysis: Results are analyzed in terms of the clinical characteristics and 
laboratory parameters at diagnosis, response to the androgenic steroids, the survival 
patterns and the parameters predicting response to androgenic steroids. The response 
to treatment is assessed in terms of Complete Response (CR), Partial response (PR), 
No response, and death. CR in severe aplastic anemia was defined as haemoglobin 
normal for age, neutrophil count >1.5 x 109/L and platelet count >150 x109/L (50). 
Partial response in severe aplastic anemia is defined as transfusion independence or 
no longer meeting the criteria for severe disease (50). Complete response in nonsevere 
aplastic anemia is defined by the same criteria as in severe aplastic anemia(50). Partial 
response in nonsevere aplastic anemia is defined as transfusion independence or 
doubling or normalisation of atleast one cell line or increase in baseline haemoglobin 
> 30g/L (if initially <6), or increase in the baseline neutrophils > 0.5x 109/L (if 
initially <0.5) or increase in the baseline platelet >20 x 109/L (if initially <20 (50).  
All patients started on treatment with androgenic steroids and with a minimum 
follow up of 12 weeks were considered evaluable for response and outcome. The 
closing date for analysis was March 31, 2014.  
 
Statistics:  Descriptive statistics were calculated for all variables. Differences in 
proportions were assessed using the chi-square statistic or Fisher exact test. 
Differences in means were tested using a t-test or Mann-Whitney-U test as 
appropriate. The relationships of clinical features to the outcome of the procedure 
were analyzed by univariate logistic regression model. For all tests, a 2-sided P-value 
of 0.05 or less was considered statistically significant. SPSS 16.0 software was used 
for the analysis.  
 
  
 
Results 
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RESULTS:  
 Between January 2008 and December 2012, a total of  8980 out patients were 
seen in the Haematology department, of which 1065 (3.67%) were diagnosed to have 
Aplastic anemia – both constitutional and acquired. Of this only 97 (9.1%) patients 
received  androgenic steroid as first line treatment, while 208 (19.5%) received ATG, 
334 (31.4%) were given CSA, 84 (7.9%) underwent Allogeneic PBSCT and the 
remaining 342 (32.1%)  patients had received androgenic steroids after receiving 
other therapies.  
 
There were a total of 97 patients diagnosed to have acquired aplastic anemia and who 
received androgenic steroids as initial therapy who fulfilled the inclusion criteria for 
the study.  Out of this 77 (79.3%) were adults (age ≥15 years) and 22 (20.7%) were 
children (age 1-14 years).   
  
DEMOGRAPHY & CLINICAL FEATURES AT DIAGNOSIS: (Table: 1) 
The median age of the 97 patients was 30 years (range: 1-79 years). Twenty (20.6%) 
patients belonged to the age group of less than 15 years .  Males were predominantly 
represented in the study group i.e. 55 (56.7%) males and 42 (43.3%) females. The 
male female ratio was 1.3:1. They were patients from different states of the country 
and two patients from outside country (Bhutan). 
Fatigue (due to anemia) and bleeding manifestations were the common presenting 
symptoms; i.e. in 87.6% (n=85) and 60.8% (n=59) respectively. Bleeding 
manifestations were mainly minor muco-cutaneous bleeds with 3 (3%) patients 
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presenting with life threatening bleed ie; one patient presented with sub-arachnoid 
haemorrhage and 2 patients were with intra-cerebral bleed 
 Thirty five (36.1%) patients had history of infections.  This included mainly recurrent 
febrile episodes with no obvious focus. None of them had presented with life 
threatening infections.  The median duration of symptoms was 60 days (range: 11-730 
days).  
All patients except one had received blood product supports (packed red cells and or 
platelet rich concentrates) prior to presentation to our Institution. 
No patient gave history of exposure to drugs, toxic chemicals, prior history of cancer 
or their treatment either chemotherapy or radiotherapy. Six patients (6.2%) had 
history of jaundice prior to onset of illness which was treated elsewhere. The median 
duration of onset of jaundice to symptoms of aplastic anemia was three months. None 
of these six patients were positive for viral serology.  
 
LABORATORY PARAMETERS AT DIAGNOSIS: (Tables: 2 and 3) 
All 97 patients had their diagnosis confirmed by the International Agranulocytosis 
and Aplastic Anemia Study Group diagnostic criteria described before. Bone marrow 
examination (aspirate and biopsy) was done in all patients.   
Majority of the patients 62 (63.9%) presented with pancytopenia. The median 
hemoglobin at presentation for the entire cohort was 6.9g/dl (range: 1.7-14.1g/dl), 
with 37 (38.1%) presenting with a hemoglobin <6g/dl. The median white cell count 
for the 97 patients was 3300/mm3 (range:700-13300), while the median absolute 
neutrophil count (ANC) for these patients was  870 mm3 (range: 0-9975). The ANC 
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was <500/ mm3 in 28 (28.8%) patients while 7 (7.2%)  out of this had an ANC <200/ 
mm3, falling into the category of very severe aplastic anemia (VSAA). The absolute 
reticulocyte count (ARC) was available in 79 (81.4%) patients. The median ARC for 
these patients was 4012 / mm3 (range: 199-61537), and majority 78 (98.7%)  had a 
count below 20000/ mm3. The median platelet count at presentation for the entire 
cohort was 8500/ mm3 (range: 2000-46000), with 79 (81.4%) presenting with a severe 
thrombocytopenia (below 20000/ mm3). 
On categorizing the patients according to the severity (table:3), majority (63.9%; 
n=62) belonged to the severe group, while 28 (28.9%) were non-severe and 7 (7.2%)  
had very severe Aplastic anemia at diagnosis. 
 
TREATMENT AND RESPONSE: (Tables: 4 and 5; Figure: 1) 
Among the total 97 patients included in the study, 83 (85.6%) opted for treatment 
with androgenic steroids because of financial reasons, while 14 (14.4%) was started 
on androgens as a bridge therapy before taking up for allogeneic stem cell transplant 
or ATG therapy, .   
Out of the 97 patients, 59 patients (60.8%) received Stanozolol and 38 patients 
(39.2%) received Danazol. All but 4 of the patients in the Stanozolol group were 
males (n=55) while all patients in the Danazol group were females (n=38). Response 
to therapy was assessed at 3months, and 6 months. Adults (≥ 15 years) and children 
(1-14 years) are analysed as a single group for all the parameters, while the response 
to treatment has been analysed separately for adults and children. At 6 months follow 
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up, there were 27 patients who were lost to follow up, and there were excluded from 
analysis at that time point. 
Among adults, at 3 months none of the patients attained complete response, 23 
patients (29.9%) showed partial response, 50 patients (64.9%) had no response and 
data was incomplete in four patients (4.2%).  At 6 months, 1 adult patient (3.3%) who 
was in PR at 3 months showed  complete response, while 30 patients (38.9%) were 
noted to be in PR. Among these patients 10 patients were already in PR at 3 month 
post treatment, while 20 patients with no response at 3 months had attained PR at 6 
months. Fourty six (59.7%) patients showed either no response to treatment (n=26) or 
were lost to follow to follow up (n=20) at 6 months.   
The median time to response was 3 months (range; 1-6 months) in both Stanozolol 
and Danazol group. The median duration of follow up was 15 months (3-60 months). 
Among children at 3 months follow up, none of the patients attained complete 
response, 7 patients (35%) showed partial response and 13 patients (65%) had no 
response to treatment. At 6 months, 1 child (5%) had shown complete response (this 
child was in PR at 3months follow up). Seven (35%) out of the 20 children showed 
PR at 6months (of these six children were in PR at 3 months while one was in NR at 3 
months follow up post treatment)., and 5 patients (60%) had no response to treatment 
at 6 months.  
The median time to response was 3 months (1-6 months) in the Stanozolol group, 
while in the Danazol group the median time to response was shorter ie; 2.5 months (2-
3 months; p value=0.721).  The median duration of follow up was 15 months (3-60 
months). 
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Out of the cohort of 97 patients, at six months follow up, 40 patients (41.2%) were 
responders (CR+PR), and 57 patients (58.8%) were non-responders. 
 
FACTORS PREDICTING RESPONSE TO TREATMENT: (Table: 6). 
In the present study, none of the patients who showed response to treatment had lost 
response while on follow up. All patients who showed response (either PR or CR) 
were considered as responders even if they were subsequently lost to follow up.  All 
those who did not show response till last follow up date were considered as non-
responders (NR). A detailed analysis was done of factors affecting response. No 
significant association was found with age (p=0.927), gender (p=0.127), duration of 
illness (p=0.119), ANC (p=0.444), Absolute reticulocyte count (p=0.781), or severity 
of illness (p=0.266). However, the better response rate noted in the Danazol group 
(52.6% versus 33.9%) was found to be near significant (p=0.069). 
 
TREATMENT RELATED MORBIDITY: (Table: 7) 
Fifteen (15.4%) patients had developed deranged liver function (transaminitis) tests 
while on follow up. Out of these only two patients (2.1%), had significant (more than 
5 times the normal) transaminitis leading to stoppage of the drug; both were in the 
Stanozolol group. None of the patients had documented hirsutism, voice change, acne 
or gastric irritation which is other common side effects of androgenic steroids. 19 
(19.6%) patients had infections requiring hospitalization during the follow-up period. 
Out of this 7 patients had bacterial sepsis with documented bacteremia, while 4 were 
life threatening with septic shock requiring ICU admission. Suspected fungal 
pneumonia was found in 5 patients (based on radiological evidence), while one 
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patient had tissue proven rhinocerebral mucormycosis. The rest of the patients had a 
host of other infections ie; gastro-enteritis (n=3), Gluteal abscess (n=1), pyogenic 
arthritis (n=1), urinary tract infection (n=1), hydradenitis (n=1) and osteomyelitis 
(n=1).  
Eleven patients (11.3%) had bleeding requiring hospitalization during the follow-up 
period which included intra-cerebral (n=4), gastrointestinal (n=3) and genitourinary 
bleeding (n=2) and oro-pharyngeal (n=2). 
 
TREATMENT STATUS AT LAST FOLLOW-UP: (Table 8) 
At last follow up 63 (64.9%) patients (53 adults and 10 children) were still on 
androgens, while 34 (35.1%) patients had either stopped treatment or opted for other 
treatment modalities or were lost to follow up. Out of the total cohort, 40 (41.2%) 
were responders (CR+PR) while 57 (58.8%) were non-responders.  
23 out of the 57 non-responders had opted for other treatment modalities ie’; 
allogeneic stem cell transplant [SCT] (n=5), Antithymocyte globulin (n=9), or 
Cyclosporine (n=9). 
All patients who underwent allogeneic SCT had matched related donors; four patients 
(80%) were children.  Four out of the five patients achieved complete response post 
allogeneic SCT. The child who failed SCT had engraftment failure post second 
transplant and died subsequently of sepsis.  
Out of nine patients (11.1%) who received Antithymocyte globulin, one had complete 
response, three had partial response and five had no response.  
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Two (22.2%) of the nine patients who received Cyclosporine had partial response, 
while the rest had no response. 
 
SURVIVAL: 
The median duration of follow up of the entire cohort of patients (n=97) was 15 
months (3- 60months). All except two patients were alive at the time of last visit. One 
patient who died had refractory septic shock due to overwhelming infection and the 
other patient died of refractory sepsis following engraftment failure post second stem 
cell transplant. The mortality rate observed in this study do not reflect the actual 
scenario as there was no follow up data for many patients. An attempt to trace these 
patients could not be made due to technical reasons (non –availability of proper 
contact details). None of patient who responded to treatment at any point of time 
during the study period, had lost response during the subsequent follow up period. 
None of the patients had progressed to Myelodysplastic syndrome or acute leukemia 
during the entire follow up period. 
 
 
 
 
 
 
 
 
 
30 
 
TABLES AND FIGURES: 
 
Table: 1 DEMOGRAPHY & CLINICAL FEATURES AT DIAGNOSIS (n = 97)   
 
Variable n (%) /median (Range) 
Median age at diagnosis in years                                    30 (1-79) 
Gender 
                                        Male 
                                        Female 
 
55 (56.7) 
42 (43.3) 
Symptoms at diagnosis 
Fatigue (due to anemia) 
Bleeding* 
Infection 
 
85 (87.6) 
59 (60.8) 
35 (36.1) 
Duration of symptoms at diagnosis in days 60 (11 -730) 
  
* Three patients had life threatening bleed. One patient presented with sub-arachnoid 
haemorrhage and 2 patients were with intra-cerebral bleed.  
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Table 2: LABORATORY PARAMETERS AT DIAGNOSIS (n=97) 
 
 
             Variable n (%) /median (Range) 
Haemoglobin (g/dl)  6.9 (1.7-14.1) 
Total White Cell Count (cells/mm3)  3300 (700-13300) 
Absolute Neutrophil Count (cells/mm3)  870 (0-9975) 
Absolute Reticulocyte Count  (cells/mm3) (n=79) 4012 (199 -61537) 
Platelet Count (cells/mm3)  8500 (2000-46000) 
 
 
 
 
Table 3: CLASSIFICATION OF SEVERITY* AT DIAGNOSIS  (n=97) 
 
Severity 
 
n (%) 
  
Non Severe 
 
28(28.9%) 
  
Severe 
 
62(63.9%) 
  
Very Severe 
 
7(7.2%) 
*International Aplastic Anemia Study Group classification 
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TREATMENT AND RESPONSE  
Table 4: RESPONSE TO ANDROGENIC STEROIDS IN ADULTS  (n=77) 
 
 Stanozolol 
n (%) 
Danazol 
n (%) 
P value 
No. of patients      44 (57.1)     33 (42.8) - 
Male:Female        41 : 3      0 : 33 - 
Response status (n=73)* 
At 3 months  
CR 
PR 
NR 
 
 
 
0 (0%) 
9 (20.4) 
35 (79.6) 
 
 
 
0 (0%) 
14 (42.4) 
15 (45.4) 
 
 
 
- 
0.020 
- 
 
At 6 months (n=57) 
CR 
PR 
NR 
 
1(3.3) 
12(40) 
17(56.7) 
 
0 (0) 
18(66.7) 
9(33.3) 
 
- 
0.105 
- 
 
Time to response in months; median (range) 
 
3(1-6) 
 
3(1-6) 
 
0.678 
* In four patients, data was incomplete  
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Table 5: RESPONSE OF ANDROGENIC STEROIDS IN CHILDREN (n=20) 
 
 Stanozolol 
n (%) 
Danazol 
n (%) 
P value 
No. of patients       15 (75)     5 (25) - 
Male : Female       14:1      0:5 - 
Response status (n=20) 
At 3 months  
CR 
PR 
NR 
 
 
0 (0) 
5 (33.3) 
10 (67.7) 
 
 
0 (0) 
2 (40) 
3 (60) 
 
 
1.0 
- 
- 
At 6 months (n=13) 
CR 
PR 
NR 
 
1(11.1) 
5 (55.6) 
3 (33.3) 
 
0 (0) 
2 (50) 
2 (50) 
 
- 
0.719 
- 
Time to response in months; 
median (range)  
 
3 (1-6) 
 
2.5 (2-3) 
 
0.721 
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Table 6:  FACTORS PREDICTING RESPONSE TO TREATMENT (n=97) 
 
 
 
 
 
Table 7:  MORBIDITY & MORTALITY: 
Variables n (%) 
Infections    19 (19.6) 
Bleeding manifestations 11 (11.3) 
Drug toxicity-Transaminitis 
Transaminitis with stoppage of therapy 
15 (15.5) 
2 (2.0) 
Mortality  2 (2.0) 
                
Variables Responders (n=40) 
n (%) / Median(range) 
Non-responders (n=57) 
n (%) / Median (range) 
RR 95% CI P-value 
Median age at 
diagnosis (yrs)       
 
 
31 (1-79) 
 
30 (2-70) 
 
1.0 
 
0.97-1.02 
 
0.927 
Sex:              Male 
 Female          
19(34.5) 
21(50) 
36(65.5) 
21(50) 
1.0 
1.9 
 
0.83-4.31 
 
0.127 
Duration of Illness:                   
                 <60 days 
               >60 days 
 
24 (49) 
16 (33.3) 
 
25 (51) 
32 (66.7) 
 
1.0 
0.5 
 
 
0.23-1.18 
 
 
0.119 
Drug type:       
               Stanozolol  
Danazol 
 
20 (33.9) 
20 (52.6) 
 
39 (66.1) 
18 (47.4) 
 
1.0 
2.2 
 
 
0.94-4.99 
 
 
0.069 
Severity of disease:     
    SAA& very SAA             
       Non-severe AA 
 
26 (37.7) 
14 (50) 
 
43 (62.3) 
14 (50) 
 
0.6 
1.0 
 
 
0.25-1.46 
 
 
0.266 
Median ANC at 
diagnosis 
(cells/mm
3
) 
 
889 (0-9975) 
 
816 (120-5390) 
 
1.0 
 
1.00-1.00 
 
0.444 
Median ARC at 
diagnosis 
(cells/mm
3
) [n=79] 
 
4780 (199-12301) 
 
3411 (700-61537) 
 
1.0 
 
1.00-1.00 
 
0.781 
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Table: 8 TREATMENT STATUS ON FOLLOW UP (n=97) 
 
  Adults 
(n=77) 
n (%) 
Children 
(n=20) 
n (%) 
Status at change of 
treatment   
Response to second line 
treatment  
PR 
n (%) 
NR 
n (%) 
CR 
n (%) 
PR 
n (%) 
NR 
n (%) 
Continued 
on 
androgens 
53 (68.8) 10 (50)    -  -  -  -  - 
Changed to 
ATG 
7 (9) 2 (10) 1 (11.1) 8 (88.9) 1 (11.1) 3 (33.3) 5 (55.6) 
Changed to 
CSA 
7 (9) 2 (10) 0 9 (100) 0 2 (22.2) 7 (77.8) 
Underwent 
Allog. 
PBSCT 
1 (0) 4 (20) 0 5 (100) 4 (80) 0 1 (20) 
Unknown   9 (11.7) 2 (10) - - - - - 
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Figure: 1 REASON FOR CHOICE OF ANDROGENS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial (n=83/85.6%)
Bridge therapy prior to
transplant/ATG,
n=14(14.4%)
85.6% 
14.4% 
  
 
Discussion 
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DISCUSSION 
Aplastic anemia is a heterogenous disease with wide variations in outcomes, with 
some people being transfusion independent and surviving longer while some others 
having a rapid downhill course culminating in death. In the present scenario there is 
no doubt regarding the treatment, in that for transplant eligible who have a fully 
matched sibling, stem cell transplantation is the most efficacious. However in 
transplant ineligible patients either because of age, comorbidities, lack of a donor or 
finances, medical therapies including androgens are a viable option. Here an attempt 
was made to study the demographic profile and response to androgens in treatment 
naïve patients who were treated in Christian Medical College, Vellore from January 
2008 - December 2012.  
During the study period there were 28980 patients seen in the outpatient unit of 
department of Haematology, out of which 1065 (3.67%) cases were diagnosed to have 
Aplastic Anemia. This study includes 97 treatment naïve patients who opted for 
androgens as first line treatment.  
The median age of the 97 patients studied was 30 years (range: 1-79). Twenty 
(20.6%) patients belonged to the age group of less than 15 years.  Males were 
predominantly represented in the study group i.e. 55 (56.7%) versus 42 (43.3%) 
females. In a study published in 1965 in British Medical journal by Lewis et al from 
Postgraduate Medical School in London, the youngest patient was 2 years old and the 
oldest was 80. There was no significant preponderance of either sex in the series as a 
whole or in any age-group, except for a (presumably chance) finding that all the 
patients between the ages of 35 and 40 were women (5). There was no such 
preponderance in this study. The data from the international study group of aplastic 
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anemia and agranulocytosis published in 2008 shows that the median age of patients 
at diagnosis was 53 years (95% confidence interval [CI] 44–58; range, 2-90). The 
median age group in this series was reported to be older than that observed in the 
present study ( 53 years versus 30 years) (49) . The younger age in this study may 
reflect the distribution of population as well as reflects the influence of different 
environmental and genetic factors contributing to the disease. 
The median duration of illness from onset to diagnosis in the present study was 60 
days. Though neutropenia is common, infection as presenting symptom is very rare 
(young et al, 2012) (48). This is true in this study where most common symptom is 
fatigue (87.6%), followed by bleeding (60.8%) and infection (36.1%). But in the case 
series by Goswami et al (2009) from Northern districts of west Bengal, symptoms of 
anemia was seen in all cases, fever in 76.1% cases and bleeding in 47.61% cases. 
Many drugs and toxic agents have been proposed as etiology in a case of aplastic 
anemia. No exposure to these drugs or toxic chemicals was evident from the history in 
this study. In the prospective multicenter study from Barcelona, out of the 235 cases, 
49 (20.8%) had history of exposure to drugs and 21 (8.9%) had exposure to toxic 
agents. The fact that this is a retrospective study and the group studied was small is 
the limitations to these data. 
Six patients (6.2%) had history of jaundice prior to onset of illness which was treated 
elsewhere. The median duration of onset of jaundice to symptoms of aplastic anemia 
was three months. None of them were noted to be positive for hepatitis virus serology. 
Four of these six patients were males and had a median age of 35 years. There was no 
difference in the outcome of this group of patients compared to the rest. This data is 
similar to the data published by Safadi et al, in 2001, which showed an interval 
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between onset of hepatitis and that of AA of 14–225 days (mean 62.3). Length of the 
interval was unrelated to age, sex or severity of hepatitis. Hepatitis associated Aplastic 
anemia (HAAA) cases reported in previous studies were generally younger (18 to 20 
years) than in the present study (ie; 35 years). Most were male, similar to this study 
(51). 
Majority of the patients 62 (63.9%) presented with pancytopenia. The median 
hemoglobin at presentation for the entire cohort was 6.9g/dl (range: 1.7-14.1g/dl), 
with 37 (38.1%) presenting with a hemoglobin <6g/dl. The median white cell count 
for the 97 patients was 3.300/mm3 (range:700-13300), while the median absolute 
neutrophil count (ANC) for these patients was  870 mm3 (range: 0-9975). The ANC 
was <500/ mm3 in 28 (28.8%) patients while 7 (7.2%) out of this had an ANC <200/ 
mm3, falling into the category of very severe aplastic anemia (VSAA). The absolute 
reticulocyte count (ARC) was available in 79 (81.4%) patients. The median ARC for 
these patients was 4012 / mm3 (range: 199-61537), and majority 78 (98.7%)  had a 
count below 20000/ mm3. In the present study, all patients had thrombocytopenia and 
the median platelet count at presentation for the entire cohort was 8500/ mm3 
(range:2000-46000), with 79 (81.4%) presenting with a severe thrombocytopenia 
(below 20000/ mm3). In the study by Gupta and Tripati from BHU, Varanasi in 2008 
on 45 patients with AA, the mean hemoglobin was 3.3 g/dL (range 2-6 g/dl) which 
was much lower than the values in this study (52). The higher hemoglobin value 
observed in the present study may be because of the prior transfusions these patients 
had received before presenting to our Institute. However the mean total leukocyte 
count (TLC) & absolute neutrophil count (ANC) were similar to that observed in the 
present study ie; 2.8 × 10 9 /L, 0.6 × 10 9 /L. In a study by Lewis et al in 1965, the 
anaemia was usually severe, with lowest levels of haemoglobin between 3 and 8.8 
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g./dl(5). Almost all cases had an absolute reticulocytopenia at some stage. This is 
similar to the present patient group in that all patients had reticulocytopenia at 
diagnosis. The neutrophil count was also usually low, but in half the cases it was 
normal on occasions. By contrast the platelets were almost invariably lower than 
normal which is similar to this study.   
On categorizing the patients according to the severity groups as proposed by camitta 
et al in 1976 (41) and Bacigalupo et al in 1988 (53), majority (63.9%; n=62) belonged 
to the severe group, with 28 (28.9%) belonging to nonsevere and 7 (7.2%) belonging 
to the very severe group.  This distribution is similar to most population studies like 
the one conducted in Barcelona, Spain in 1980 where 83.8% patients belonged to 
severe or very severe group. 
 All ninety seven patients who had atleast one follow up visit at three months after 
initiation of therapy were evaluated for response. An adequate course of androgen is 
difficult to define, but most clinicians agree that as long as 3 months of treatment may 
be required to induce an erythropoietic effect in patients with bone marrow failure of 
diverse etiologies. A rise in the neutrophil and platelet counts usually may be even 
more delayed. Fifty nine patients (60.8%) received Stanozolol and 38 patients 
(39.2%) received Danazol. However a detailed search did not yield any reports 
comparing Stanozolol with Danazol. The response status for the entire cohort at any 
point between 3 and 6 months was analysed. 
Overall at six months follow up, 40 patients (41.2%) were found to be responders (CR 
+ PR), and 57 patients (58.8%) were nonresponders ie. 37.7% (n=26) patients in 
severe and very severe AA groups had responded to therapy and 50% (n=14) patients 
in the nonsevere group had responded to treatment with androgenic steroids.  The 
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median time to response was 3 (1-6) months. Literature review has showed that a 
study from Chandigarh, India in 1991-2000, retrospectively analysed 49 children with 
aplastic anemia including constitutional aplastic anemia who were treated with 
Stanozolol and found that none of patients with very severe Aplastic anemia 
responded to therapy (39). In our series, 28.6% patients with severe aplastic anemia 
responded and 38% of patients with nonsevere aplastic anemia responded to 
treatment. This observation is similar to that in the present study ie; response to 
androgenic steroid was better in the non-severe groups than the severe or very severe 
groups. The median time to response reported was also noted to be similar to that in 
the present study ie 11 weeks versus 12 weeks (in the present study).  
Jaime-Perez J C and collegues, studying the effectiveness of Danazol as first line 
treatment of aplastic anemia in 2011, reported an overall response rate 46% (17/37) in 
the danazol-treated group with the median time to initial response of 3 months (1-27), 
reflecting the observation in the present study(40). Tendency to achieve remission 
was similar among severity groups (P  =  0.094). These results match the results of 
our study where there was no difference between the severity groups (p=0.266). The 
study by Camitta et al in 1979 totally contradicts our study, in that it failed to show 
any response to androgens (41). However this study has many limitations, important 
one being that this study was a retrospective analysis conducted on patients with only 
severe aplastic anemia whereas previous studies have shown that androgens work 
better in patients with non-severe disease. 
Among adults at 3 months follow up, the responders in the Danazol group was found 
to be significantly superior to that in the Stanozolol group ie; 42.4% versus 20.4% (p 
value 0.02). However the response status analysed at 6 months follow up among 
adults was not observed to statistically significant among the two drug groups (ie; 
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66.7%  in Danazol group versus 43.3% in Stanozolol group; p value= 0.105). Among 
children no significant difference in response rate was observed between the drug 
groups at 3 or 6 months. A literature search did not reveal any similar studies for 
comparison of these observations. 
The common side effects of Androgen treatment are  virilization, fluid retention, 
hyperlipidemia, acne, and more seriously, hepatic toxicity with cholestatic jaundice, 
peliosis hepatitis (42), and rarely, hepatoma (43). In this study the only side effect 
documented was transaminitis which resolved with stoppage of therapy. 
A univariate logistic regression analysis of the common variables was done to detect 
predictors of response to treatment. This showed no significant association with age 
(0.927), gender (p=0.127), duration of illness (p=0.119), ANC (p=0.444), Absolute 
reticulocyte count (p=0.781), or severity of illness (p=0.266) at diagnosis with the 
response status. However a near significant association was observed with the type of 
drug (ie; Danazol 52.6% versus Stanozolol 33.9%; p value= 0.069). A similar result 
can be seen in a study by Champlin et al in 1985, who compared three treatment 
groups, patients who received ATG alone, ATG + androgens and ATG historical 
controls (54). There was no statistically significant difference in the response rates 
between three groups if patients are stratified by age, sex, bone marrow cellularity, or 
etiology of aplastic anemia. Pretreatment peripheral blood counts were also not 
predictive of response. Another study by Sanchez Medal in 1966 in two hospitals, 
consisted of 69 patients who received four different androgens (oxymetholone, 
methandrolone, metholone and methenolone) (55). In this study, a remission was 
attained in 33 cases ie. 47.9%. There was no influence of age, sex, bone marrow 
cellularity or etiology on the response to therapy. A moderately higher rate of 
remission was observed in females than in males (similar to our study), but the 
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difference was not significant (p = 0.2). Similarly, a higher remission rate was 
observed with aplastic anemia secondary to drugs or chemical agents (26 out of 51 
cases, or 50.9 per cent) and particularly to phenylbutazone, as compared with those 
considered as idiopathic. The difference between these remission rates, however, was 
not significant (p = 0.3 to 0.4). Only the initial reticulocyte per cent value (p=0.001) 
and the extreme neutropenia showed some relationship with the response to therapy. 
The degree of anemia or that of thrombocytopenia did not correlate well with 
response to therapy.  
 
LIMITATIONS OF THE STUDY: 
1. Retrospective study: limited available data due to non-retrievable records. 
2. This cohort of patients may not be truly representative of general population 
because of the selection bias, since most of patients presenting to the department opt 
for definitive therapy-either transplant or immunosuppressive therapy rather than 
androgenic steroids. 
3. Limited patient numbers and data available due to loss of follow up of patients. 
 
 
 
 
 
  
 
Conclusions 
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CONCLUSION: 
1. Androgens still remains a viable option in the treatment of aquired AA in 
resource constraint situations, with no major drug related adverse effects. 
2. There is no significant association between severity and response to 
androgens. 
3. Response to Danazol is superior to Stanozolol in adult patients. 
4. Further prospective studies are needed to delineate the mechanisms involved 
in androgen action and the factors predicting response to therapy.   
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MASTER CHART: 
SlNo YOD Age Sex Infection Bleeding Fatiguability 
Duration of 
illness(days) 
Major 
Bleeding 
Serious 
Infection 
Drug 
Exposure 
Chemical 
Exposure 
Jaundice 
History Tobacco Alchohol 
Family 
History  infecton 
1 2009 64 F Y Y Y 25 N N N N N N N N N 
2 2013 61 M Y Y Y 60 N N N N N N N N N 
3 2011 26 M N N Y 180 N N N N N N N N Y 
4 2009 14 M Y Y Y 15 N N N N N N N N Y 
5 2008 14 M Y Y Y 45 N N N N N N N N N 
6 2008 32 F N N Y 30 N N N N N N N N N 
7 2008 27 M N N Y 90 N N N N Y N N N N 
8 2008 22 M Y Y Y 150 N N N N N N N N N 
9 2008 59 M N Y Y 365 N N N N N Y Y N N 
10 2008 30 M N Y Y 75 N N N N N N N N N 
11 2009 12 F Y Y Y 60 N N N N N N N N N 
12 2009 46 F N Y Y 210 N N N N N N N N N 
13 2009 2 M N Y N 365 N N N N N N N N N 
14 2009 34 M N Y Y 90 N N N N N N N N N 
15 2009 29 M Y N Y 90 N N N N N N N N N 
16 2009 40 M N N Y 90 N N N N N N N N N 
17 2010 54 F N Y Y 180 Y N N N N N N N N 
18 2010 5 F Y N Y 180 N N N N N N N N N 
19 2010 52 M N N Y 20 N N N N N N N N N 
20 2010 70 M N N Y 365 N N N N N Y N N N 
21 2011 52 F N N Y 30 N N N N N N N N N 
22 2011 33 M Y Y Y 90 N N N N N N N N N 
23 2012 19 F N Y Y 365 N N N N N N N N N 
24 2012 35 F N Y Y 30 N N N N N N N N Y 
25 2012 49 F N N Y 270 N N N N N N N N N 
26 2012 57 F Y Y Y 30 N N N N Y N N N N 
27 2012 27 F Y N N 120 N N N N N N N N N 
28 2012 63 M N N Y 90 N N N N Y N N N N 
29 2012 53 M N N Y 210 N N N N N N Y N N 
30 2013 45 F Y Y Y 270 N N N N N N N N N 
31 2013 29 M N Y Y 180 N N N N N N N N N 
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Sl 
No 
Hb WBC ANC ARC Platelet Severity 
Stanl/ 
Dan 
Date of 
starting 
Duration 
of Trt 
Resp. 
3 mo 
Resp. 
6 mo 
Resp. 
status 
Time 
to 
resp. 
6mo 
Time to 
Response Side Effects 
Other 
Treatment 
Current 
Status 
Date of last 
FU 
1 5.4 2400 408 NA 10000 S S 17-04-2009 6 1 0 0  0 NR N N 1 09-10-2009 
2 4.6 2400 1200 61537 11000 NS S 10-05-2013 6 1 1 0  0 NA N A 1 14-03-2014 
3 3.5 2300 322 1822 6000 S S 19-04-2011 16 1 1 0  0 8 N A 1 07-01-2014 
4 5 3000 120 2751 5000 VS S 16-10-2009 6 1 1 0  0 NA 1 A 1 14-01-2014 
5 4.7 3300 330 2349 4000 S S 29-12-2008 6 1 1 0  0 NA N C 1 23-07-2013 
6 4 3000 1140 2702.2 17000 S D 29-04-2008 12 1 1 0  0 9 N N 1 19-05-2009 
7 2.7 2800 1456 2466 19000 S S 15-07-2008 15 1 1 0  0 NA N N 1 26-06-2010 
8 2.7 5500 825 NA 9000 NS S 19-08-2008 18 1 1 0  0 18 N N 1 18-02-2010 
9 6.2 2700 1242 4653.6 6000 S S 29-08-2008 9 1 1 0  0 NA N N 1 08-05-2009 
10 8.5 3500 1295 NA 5000 NS S 31-10-2008 51 1 1 0  0 NA N C 1 19-01-2013 
11 6.3 4400 1100 4118.1 13000 S D 13-01-2009 5 1 1 0  0 NR N T 1 07-11-2013 
12 5.6 2300 276 NA 10000 S D 24-02-2009 12 NA NA 0  0 NA N N 1 26-02-2010 
13 12.3 4800 720 3854.4 10000 S S 19-05-2009 9 1 1 0  0 NR N N 1 25-03-2010 
14 5.6 2500 900 4653.7 5000 S S 19-06-2009 12 1 1 0  0 NR N N 1 18-05-2010 
15 5.4 2700 756 3411.2 3000 S S 28-07-2009 25 1 1 0  0 19 N N 1 26-08-2011 
16 9.6 7700 5390 5699.2 29000 NS S 18-08-2009 8 1 1 0  0 NA N N 1 25-04-2010 
17 6.2 2500 950 NA 11000 NS S 16-02-2010 20 1 1 0  0 NA N C 1 21-09-2011 
18 6.9 3900 156 3707.4 6000 VS D 22-06-2010 27 1 1 0  0 9 N N 1 12-11-2012 
19 5.6 4600 1932 NA 10000 NS S 22-10-2010 9 1 1 0  0 NA N N 1 27-06-2011 
20 3.9 4600 1932 NA 7000 NS S 15-11-2010 12 1 1 0  0 NA N N 1 30-11-2011 
21 4 5100 1122 4259.8 8000 S D 13-05-2011 6 1 1 0  0 NA N C 1 20-12-2013 
22 6.3 3600 1440 NA 8000 NS S 14-10-2011 15 1 1 0  0 NA N N 1 09-01-2013 
23 7.5 2700 540 3390.2 9000 S D 20-01-2012 24 1 1 0  0 21 N N 1 20-12-2013 
24 5.4 6700 4154 2836.2 8000 S D 19-06-2012 21 1 1 0  0 NA N N 1 17-03-2014 
25 6.9 2700 1080 5103.5 36000 NS D 13-03-2012 17 NA NA 0  0 17 N N 1 27-08-2013 
26 8.8 1800 1008 3718 41000 NS D 10-07-2012 18 1 1 0  0 9 N N 1 03-01-2014 
27 7.4 4600 2346 5638.6 30000 NS D 29-06-2012 7 1 1 0  0 NA N T 1 17-02-2014 
28 7.5 2400 576 2926 7000 S S 04-01-2013 9 1 1 0  0 NA N N 1 17-10-2013 
29 7.4 4500 1080 3285.6 19000 S S 22-03-2013 6 1 1 0  0 NA N C 1 04-03-2014 
30 7.3 2200 308 5977 5000 S D 08-03-2013 6 1 1 0  0 NA N N 1 04-02-2014 
31 11.5 3100 1085 1427.4 7000 S S 14-06-2013 7 1 1 0  0 NA N N 1 22-03-2014 
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SlNo YOD Age Sex Infection Bleeding Fatiguability 
Duration of 
illness(days) 
Major 
Bleeding 
Serious 
Infection 
Drug 
Exposure 
Chemical 
Exposure 
Jaundice 
History Tobacco Alchohol 
Family 
History  infecton 
32 2011 25 M N Y Y 30 N N N N N N N N N 
33 2008 75 F N N Y 60 N N N N N N N N N 
34 2013 47 F N Y Y 7 N N N N N NA NA NA N 
35 2008 63 M N Y Y 180 N N N N N N N N N 
36 2008 41 F N Y Y 90 Y  N N N N N N N Y 
37 2008 35 F N Y Y 120 N N N N N N N N N 
38 2008 30 M Y N N 365 N Y N N N N N N Y 
39 2008 8 F N Y N 540 N N N N N N N N Y 
40 2008 11 M Y Y Y 45 N N N N N N N N N 
41 2008 22 M N Y Y 120 N N N N N N N N N 
42 2009 19 M N Y Y 120 N N N N N N N N N 
43 2009 33 F N Y Y 180 N N N N N N N N N 
44 2009 33 F N N Y 330 N N N N N N N N N 
45 2009 56 F N N Y 180 N N N N N N N N N 
46 2009 79 F N Y Y 210 N N N N N N N N N 
47 2009 26 F N N Y 30 N N N N N N N N N 
48 2010 27 F Y Y Y 60 Y N N N N N N N N 
49 2010 49 M Y Y Y 45 N N N N N N N N N 
50 2010 45 F N N Y 60 N N N N N N N N N 
51 2010 50 M N Y Y 30 N N N N N N N N N 
52 2010 40 F N N N 30 N N N N N N N N N 
53 2010 56 F N N N 30 N N N N N N N N N 
54 2010 10 F Y N N 60 N N N N N N N N N 
55 2011 1 F Y N N 365 N N N N N N N N N 
56 2011 35 M N Y Y 30 N N N N N N N N N 
57 2011 32 F N Y Y 30 N N N N N N N N N 
58 2012 8 M N N Y 60 N N N N N N N N N 
59 2012 33 M N Y Y 30 N N N N N N N N N 
60 2012 45 F N Y Y 210 N N N N N N N N N 
61 2012 16 M N Y Y 720 N N N N N N N N N 
62 2012 8 M Y Y N 15 N N N N N N N N N 
63 2012 48 M Y N Y 45 N N N N N N N N N 
64 2012 24 F Y N Y 15 N N N N N N N N N 
65 2012 27 F Y Y Y 20 N N N N N N N N N 
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Sl 
No 
Hb WBC ANC ARC Platelet Severity 
Stanl/ 
Dan 
Date of 
starting 
Duration 
of Trt 
Resp. 
3 mo 
Resp. 
6 mo 
Resp. 
status 
Time 
to 
resp. 
6mo 
Time to 
Response 
Side 
Effects 
Other 
Treatment 
Current 
Status 
Date of last 
FU 
32 8.2 4900 588 1558 15000 S S 12-07-2011 24 1 3 1 4 4 N N 1 04-11-2013 
33 4.9 2800 532 4180 12000 S D 23-09-2008 29 3 3 1 5 5 N N 1 13-08-2013 
34 8.2 2500 800 4563 6000 S D 31-05-2013 7 3 3 1 4 4 N N 1 31-01-2014 
35 7 3600 1116 4788 18000 S S 04-04-2008 6 3 3 1 3 3 N N 1 28-10-2008 
36 11.4 4400 2288 12301 8000 S D 15-01-2008 6 3 3 1 2 2 N N 1 17-09-2010 
37 7.9 2900 522 9623.4 17000 S D 02-05-2008 9 3 3 1 3 3 N N 1 03-02-2009 
38 10.8 4600 2254 10392.9 33000 S S 22-07-2008 60 3 3 1 3 3 N N 1 06-08-2013 
39 10.4 9400 940 NA 8000 NS S 10-10-2008 9 3 3 1 3 3 N T 1 28-05-2011 
40 7.2 5300 689 4510 11000 S S 02-12-2008 24 3 3 1 1 1 N N 1 21-01-2011 
41 7 2900 957 4012.8 11000 NS S 06-01-2009 11 3 3 1 3 NR N N 1 07-12-2009 
42 10 6600 1386 9519.2 12000 S S 13-01-2009 48 3 3 1 3 9 N N 1 21-02-2013 
43 6.7 6200 2294 6570.4 20000 S D 27-01-2009 5 NA 3 1 5 5 N N 1 02-06-2009 
44 11.6 2600 1508 6867.2 46000 NS D 15-09-2009 6 NA 3 1 6 NR N N 1 14-10-2011 
45 2.3 4500 2205 NA 11000 NS D 18-08-2009 36 3 3 1 3 3 N N 1 26-02-2014 
46 12.1 4200 924 NA 8000 NS D 20-10-2009 39 1 3 1 6 6 N N 1 11-01-2013 
47 9.7 2900 696 2626.5 10000 S D 01-12-2009 31 3 3 1 2 2 N N 1 13-07-2012 
48 9.9 2100 420 6578 16000 S D 30-03-2010 16 3 3 1 1 1 N N 1 20-07-2011 
49 4.8 3300 363 NA 5000 S S 08-06-2010 9 3 3 1 3 3 N N 1 11-03-2011 
50 6.5 1600 896 5582.2 30000 NS D 31-08-2010 33 3 NA 1 3 9 N N 1 29-05-2013 
51 5.9 2500 275 1417.5 7000 S S 12-10-2010 14 1 3 1 4 4 N N 1 13-12-2011 
52 10.1 4000 1760 7950 43000 NS D 03-11-2010 27 3 3 1 3 3 N A 1 27-01-2014 
53 14.1 13300 9975 4474.3 20000 NS D 27-11-2010 38 1 3 1 6 6 N N 1 31-01-2014 
54 8.1 3100 651 8668.8 9000 S D 04-12-2010 18 3 3 1 3 3 N N 1 27-06-2012 
55 8.8 5800 870 9828 22000 NS D 08-02-2011 31 3 3 1 2 2 N N 1 03-09-2013 
56 7.2 2100 882 3821.8 16000 S S 11-10-2011 25 1 3 1 6 6 N N 1 09-10-2013 
57 5.3 4100 1271 2141.3 8000 S D 19-04-2013 10 3 3 1 1 1 N N 1 28-02-2014 
58 13.2 2800 1736 6401.4 16000 S S 23-03-2012 18 3 3 1 3 3 N N 1 27-09-2013 
59 7 4400 968 4772.2 11000 S S 13-03-2012 20 1 3 1 6 6 N N 1 02-11-2013 
60 7.3 3000 1260 4237 20000 NS D 21-03-2012 8 3 3 1 2 2 N N 1 13-11-2012 
61 9.1 3800 836 4767.2 23000 NS S 11-04-2012 18 1 3 1 4 4 N N 1 25-03-2014 
62 5.6 2900 203 4867.8 9000 S S 29-03-2012 23 3 3 1 2 2 N N 1 07-02-2014 
63 11.2 2200 682 4931.9 18000 S S 25-09-2012 13 3 3 1 1 1 N N 1 15-10-2013 
64 1.7 3500 350 2160 5000 S D 02-10-2012 12 3 3 1 3 3 N N 1 18-10-2013 
65 10.5 1600 64 2548.9 29000 VS D 28-09-2012 15 3 3 1 1 1 N N 1 31-12-2013 
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History  infecton 
66 2012 22 F N N Y 180 N N N N N N N N N 
67 2012 13 M N Y Y 11 Y N N N N N N N Y 
68 2013 24 M Y Y Y 90 N N N N N N Y N N 
69 2009 13 M Y N N 30 N N N N N N N N N 
70 2012 41 M N Y Y 60 N N N N N N Y N N 
71 2013 11 M Y Y Y 30 Y N N N N N N N Y 
72 2013 28 M Y N Y 10 N N N N N NA NA NA N 
73 2008 22 M Y Y Y 150 N N N N Y N N N Y 
74 2008 42 M N N Y 60 N N N N N N N N N 
75 2008 43 M N Y Y 730 N N N N Y N N N N 
76 2008 21 M Y Y Y 365 N N N N Y N N N N 
77 2009 59 F N Y Y 30 N N N N N N N N N 
78 2009 54 F Y N Y 90 N N N N N N N N N 
79 2009 8 M N Y Y 15 Y N N N N N N N Y 
80 2009 25 F Y Y Y 20 Y N N N N N N N N 
81 2009 11 M Y Y Y 180 N N N N N N N N N 
82 2009 12 F N N Y 7 N N N N N N N N N 
83 2009 18 M N Y Y 60 Y N N N N N N N N 
84 2010 30 F N Y Y 180 N N N N N N N N N 
85 2010 47 M N Y Y 90 N N N N N N N N N 
86 2010 34 M N Y Y 30 N N N N N N N N N 
87 2010 45 F N N Y 120 N N N N N N N N N 
88 2010 10 M N N Y 21 Y Y N N N N N N Y 
89 2011 44 M N N Y 210 N N N N N N N N N 
90 2011 10 M Y Y Y 90 N N N N N N N N N 
91 2011 8 M Y Y N 180 N N N N N N N N N 
92 2011 18 M Y N Y 60 N N N N N N N N N 
93 2012 45 M N Y Y 15 N N N N N N N N N 
94 2012 23 F N N N 30 N N N N N N N N N 
95 2012 22 M N Y Y 45 Y Y N N N N N N Y 
96 2012 26 M N N Y 45 N N N N N N N N N 
97 2012 21 F Y Y Y 30 Y Y N N N N N N Y 
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66 7.5 3900 1365 6487.2 31000 NS D 27-11-2012 10 3 3 1 3 3 N N 1 16-08-2013 
67 6.8 1400 0 198.9 3000 VS S 22-01-2013 11 1 3 1 6 NA N N 1 15-11-2013 
68 5.9 3500 280 1812.8 12000 S S 26-03-2013 9 3 3 1 3 3 N N 1 25-02-2014 
69 10.4 4700 1175 9668.5 23000 NS S 16-10-2009 12 3 4 1 3 3 N N 1 12-06-2012 
70 5.6 3300 1221 4107.6 13000 S S 22-01-2013 11 3 4 1 1 1 N N 1 07-03-2014 
71 . 3000 180 11792 6000 S S 15-05-2013 3 1 NA LFU   NA N N 1 25-10-2013 
72 2.3 700 350 2224 6000 S S 28-06-2013 3 1 NA LFU   NA N N 1 06-09-2013 
73 4.9 2200 176 3628 7000 VS S 25-01-2008 3 1 NA LFU   NA N C 1 05-09-2008 
74 9.6 3900 1521 NA 13000 NS S 10-10-2008 3 1 NA LFU   NA N C 1 22-01-2009 
75 8 3100 1023 3570 10000 S S 10-10-2008 6 1 NA LFU   NA N N 1 21-03-2009 
76 7.2 2000 280 1127 9000 S S 08-11-2008 3 1 NA LFU   NA N N 1 27-04-2009 
77 4.6 2800 280 NA 11000 S D 17-02-2009 3 1 NA LFU   NA N N 1 26-05-2009 
78 7.9 3000 450 3847.9 8000 S D 24-02-2009 4 1 NA LFU   NA N N 1 08-06-2009 
79 10.8 4100 164 700 16000 VS S 03-04-2009 3 1 NA LFU   NR N C 1 08-01-2010 
80 6.3 2400 816 NA 2000 NS S 07-04-2009 4 1 NA LFU   NA N N 1 27-02-2010 
81 9.8 4400 440 910.6 5000 S S 04-08-2009 3 1 NA LFU   NR N N 1 20-10-2009 
82 3.1 3900 1053 1780 9000 S D 13-11-2009 5 1 NA LFU   NA N T 1 23-01-2014 
83 3 3900 507 3390.8 3000 S S  22-12-2009 4 1 NA LFU   NA N N 0 20-04-2010 
84 8 2500 450 6576.6 9000 S D 13-07-2010 4 1 NA LFU   NA N C 1 27-11-2010 
85 5.1 2000 560 2783.2 6000 S S 16-03-2010 4 1 NA LFU   NA N N 1 23-07-2010 
86 4 1900 456 2101.2 5000 S S 25-06-2010 3 1 NA LFU   NA N N 1 14-09-2010 
87 4.5 3100 372 3872.6 9000 S D 24-09-2010 3 1 NA LFU   NA N N 1 31-12-2010 
88 10.6 6200 186 2550 4000 VS S 26-02-2011 3 1 NA LFU   NA N T 1 07-03-2014 
89 6.8 6300 1449 3916.8 9000 S S 08-04-2011 5 1 NA LFU   NA N A 1 07-03-2014 
90 3 4000 800 2668 7000 S S 01-06-2011 3 1 NA LFU   NA N A 1 30-09-2013 
91 5.6 3600 252 NA 12000 S S 30-09-2011 4 1 NA LFU   NA N N 1 24-01-2012 
92 6.2 4400 1056 5837.4 14000 S S 29-11-2011 3 1 NA LFU   NR N N 1 17-09-2013 
93 4.1 1800 288 NA 2000 S S 14-09-2012 3 1 NA LFU   NA N N 1 20-11-2012 
94 10.4 6700 2010 NA 13000 NS D 27-07-2012 3 1 NA LFU   NA N A 1 15-02-2014 
95 7.5 5500 1925 2242 6000 S S 28-09-2012 3 1 NA LFU   NA 1 A 1 28-02-2014 
96 5.5 2500 650 6146 23000 NS S 26-04-2008 91 3 NA LFU   3 N N 1 13-11-2012 
97 7.2 3800 2622 6466 21000 S D 05-02-2013 4 1 NA LFU   NA N A 1 18-03-2014 
 CODING  
 
1= No Response; 3= Partial response; 4=Complete Response. LFU= Lost to follow up 
 
  
